Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE)

Trial Profile

Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Domatinostat (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms EMERGE
  • Most Recent Events

    • 23 Sep 2019 According to an 4SC media release, data from this study will be presented at the European Society of Medical Oncology (ESMO) Congress being held on 27 September to 1 October 2019 in Barcelona, Spain.
    • 08 Aug 2019 According to an 4SC media release, the study is being conducted in two parts, an initial part to evaluate the safety of domatinostat in combination with checkpoint inhibitors and to determine a recommended Phase II dose, potentially followed by a second expansion part in order to obtain a larger data-set through the addition of more patients at the preferred dose. 4SC expects to publish results from part 1 of this trial in the second half of 2019.
    • 25 Jul 2019 According to a 4SC media release, the Safety Review Committee consisting of clinical and drug safety experts evaluated the safety data from the first dose cohort and recommended continuation with the second dose cohort in the study. Patient recruitment for the second dose cohort has been initiated.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top